Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Common Equity (2016 - 2025)

Dare Bioscience (DARE) has disclosed Common Equity for 11 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity rose 292.52% year-over-year to $2.9 million, compared with a TTM value of $2.9 million through Sep 2025, up 292.52%, and an annual FY2024 reading of -$6.0 million, down 19.11% over the prior year.
  • Common Equity was $2.9 million for Q3 2025 at Dare Bioscience, up from -$12.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $38.8 million in Q4 2021 and bottomed at -$12.7 million in Q2 2025.
  • Average Common Equity over 5 years is $7.5 million, with a median of $2.9 million recorded in 2025.
  • The sharpest move saw Common Equity surged 3464.87% in 2021, then crashed 576.63% in 2025.
  • Year by year, Common Equity stood at $38.8 million in 2021, then tumbled by 71.33% to $11.1 million in 2022, then plummeted by 145.42% to -$5.0 million in 2023, then decreased by 19.11% to -$6.0 million in 2024, then soared by 147.54% to $2.9 million in 2025.
  • Business Quant data shows Common Equity for DARE at $2.9 million in Q3 2025, -$12.7 million in Q2 2025, and -$9.6 million in Q1 2025.